Myocardial scintigraphy using a fatty acid analogue detects coronary artery disease in hemodialysis patients

Kidney International

Volumn 66, Issue 2, 2004, Pages 811-819

  Nishimura, Masato ^a   Hashimoto, Tetsuya ^b   Kobayashi, Hiroyuki ^b   Fukuda, Toyofumi ^b   Okino, Koji ^b   Yamamoto, Noriyuki ^b   Fujita, Hiroshi ^b   Inoue, Naoto ^b   Nishimura, Tsunehiko ^b   Ono, Toshihiko ^b  

^a Toujinkai Hospital   (Japan)

^b NONE

Author keywords

BMIPP; Coronary artery disease; End stage renal disease; Fatty acid; Hemodialysis

Indexed keywords

15 (4 IODOPHENYL) 3 METHYLPENTADECANOIC ACID I 123; FATTY ACID DERIVATIVE; THALLIUM CHLORIDE TL 201;

ADULT; AGED; ANGIOCARDIOGRAPHY; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY ARTERY OBSTRUCTION; CORONARY ARTERY SPASM; DIAGNOSTIC ACCURACY; DRUG UPTAKE; FEMALE; HEART SCINTISCANNING; HEMODIALYSIS; HUMAN; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECEIVER OPERATING CHARACTERISTIC; SCREENING; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

EID: 3242811281     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1523-1755.2004.00808.x     Document Type: Article

References (48)

1. FARIAS MA, MCCLELLAN W, SOUCIE JM, MITCH WE: A prospective comparison of methods for determining if cardiovascular disease is a predictor of mortality in dialysis patients. Am J Kidney Dis 23:382-388, 1994
2. PARFREY PS, FOLEY RN: The clinical epidemiology of cardiac disease in chronic renal failure. J Am Soc Nephrol 10:1606-1615, 1999
3. KRAMER W, WIZEMANN V, MANDELBAUM AP, RITZ E: Cardiovascular problems in uraemic patients, in Oxford Textbook of Clinical Nephrology (vol 2), edited by Cameron S, Davison AM, Grübfeld J-P, Kerr D, Ritz E, Oxford, Oxford Medical Publications, 1992, pp 1264-1278
4. MANSKE CL, THOMAS W, WANG Y, WILSON RF: Screening diabetic transplant candidates for coronary artery disease: Identification of a low risk subgroup. Kidney Int 44:617-621, 1993
5. ROSTAND SG, RUTSKY EA: Ischemic heart disease in chronic renal failure: Management considerations. Semin Dial 2:98-101, 1989
6. CONLON PJ, KRUCOFF MW, MINDA S, et al: Incidence and long-term significance of transient ST segment deviation in hemodialysis patients. Clin Nephrol 49:236-239, 1998
7. DAHAN M, VIRON BM, FARAGGI M, et al: Diagnostic accuracy and prognostic value of combined dipyridamole-exercise thallium imaging in hemodialysis patients. Kidney Int 54:255-262, 1998
8. DAHAN M, VIRON BM, POISEAU E, et al: Combined dipyridamole-exercise stress echocardiography for detection of myocardial ischemia in hemodialysis patients: An alternative to stress nuclear imaging. Am J Kidney Dis 40:737-744, 2002
9. REIS G, MARCOVITZ PA, LEICHTMAN AB, et al: Usefulness of dobutamine stress echocardiography in detecting coronary artery disease in end-stage renal disease. Am J Cardiol 75:707-710, 1995
10. NEELY R, ROVETTO J, ORAM F: Myocardial utilization of carbohydrate and lipids. Prog Cardiovasc Dis 15:289-299, 1972
11. LOPASCHUK GD, BELKE DD, GAMBLE J, et al: Regulation of fatty acid oxidation in the mammalian heart in health and disease. Biochimica et Biophysica Acta 1213:263-276, 1994
12. KNAPP FF JR, FRANKEN P, KROPP J: Cardiac SPECT with iodine-123-labeled fatty acids: Evaluation of myocardial viability with BMIPP. J Nucl Med 36:1022-1030, 1955
13. TATENO M, TAMAKI N, YUKIHIRO M, et al: Assessment of fatty acid uptake in ischemic heart disease without myocardial infarction. J Nucl Med 37:1981-1985, 1996
14. FUJIWARA S, TAKEISHI Y, ATSUMI H, et al: Fatty acid metabolic imaging with iodine- 123-BMIPP for the diagnosis of coronary artery disease. J Nucl Med 38:175-180, 1997
15. TAKEISHI Y, FUJIWARA S, ATSUMI H, et al: Iodine-123-BMIPP imaging in unstable angina: A guide for interventional strategy. J Nucl Med 38:1407-1411, 1997
16. SUZUKI A, TAKADA Y, NAGASAKA M, et al: Comparison of resting β-methyliodophenyl pentadecanoic acid (BMIPP) and thallium-201 tomography using quantitative polar maps in patients with unstable angina. Jpn Circ J 61:133-138, 1997
17. MISUMI I, KIMURA Y, HOKAMURA Y, et al: Myocardial rest iodine-123-β-methyliodophenyl pentadecanoic acid scintigraphy compared with dipyridamole stress thallium-201 scintigraphy in unstable angina. Internal Med 37:21-26, 1998
18. 123I-BMIPP scintigraphy in diagnosis of effort angina pectoris with reference to subsets of the disease. Ann Nucl Med 12:139-144, 1998
19. MORIMOTO K, TOMODA H, YOSHITAKE M, et al: Prediction of coronary artery lesions in unstable angina by iodine 123 beta-methyl iodophenyl pentadecanoic acid (BMIPP), a fatty acid analogue, single photon emission computed tomography at rest. Angiology 50:639-648, 1999
20. WATANABE K, OHTA Y, TOBA K, et al: Abnormal fatty acid metabolism in patients with coronary spasm. Ann Nucl Med 13:33-41, 1999
21. 123I-BMIPP scintigraphy for detection of organic coronary stenosis and therapeutic outcome in patients with chest pain. Ann Nucl Med 14:187-192, 2000
22. KAWAI Y, TSUKAMOTO E, NAZAKI Y, et al: Significance of reduced uptake of iodinated fatty acid analogue for the evaluation of patients with acute chest pain. J Am Coll Cardiol 38:1888-1894, 2001
23. CERQUEIRA MD, WEISSMAN NJ, DILSIZIAN V, et al, FOR THE AMERICAN HEART ASSOCIATION WRITING GROUP ON MYOCARDIAL SEGMENTATION AND REGISTRATION FOR CARDIAC IMAGING: Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart - A statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association. Circulation 105:539-542, 2002
24. YAMAMICHI Y, KUSUOKA H, MORISHITA K, et al: Metabolism of iodine-123-BMIPP in perfused rat hearts. J Nucl Med 36:1043-1050, 1995
25. TANAKA T, OKAMOTO F, SOHMIYA K, KAWAMURA K: Lack of myocardial iodine-123 15-(p-iodiphenyl)-3-R, S-methyl pentadecanoic acid (BMIPP) uptake and CD36 abnormality. Jpn Circ J 61:724-725, 1997
26. 123I-15-(p-iodophenyl)-3- R,S-methyl pentadecanoic acid myocardial single photon emission computed tomography in a 55-year-old woman. Jpn Circ J 63:732-736, 1999
27. FUJIBAYASHI Y, YONEKURA Y, TAKEMURA Y, et al: Myocardial accumulation of iodinated beta-methyl-branched fatty acid analogue, iodine-125-15-(p-iodophenyl) - 3-(R,S)methyl pentadecanoic acid (BMIPP), in relation to ATP concentration. J Nucl Med 31:1818-1822, 1990
28. FUJIBAYASHI Y, NOHARA R, HOSOKAWA R, et al: Metabolism and kinetics of iodine- 123-BMIPP in canine myocardium. J Nucl Med 37:757-761, 1996
29. HOSOKAWA R, NOHARA R, FUJIBAYASHI Y, et al: Metabolic fate of iodine-123-BMIPP in canine myocardium after administration of etomoxir. J Nucl Med 37:1836-1840, 1996
30. HOSOKAWA R, NOHARA R, FUJIBAYASHI Y, et al: Myocardial kinetics of iodine-123-BMIPP in canine myocardium after regional ischemia and reperfusion: Implications for clinical SPECT. J Nucl Med 38:1857-1863, 1997
31. AMANN K, WIEST G, NEUSÜß R, et al: Changes in vascular architecture independent of blood pressure in experimental uremia. Vascular hypertrophy in uremia is independent of hypertension. Am J Hypertens 8:409-417, 1995
32. BARENBROCK M, SPIEKER C, LASKE V, et al: Studies of vessel wall properties in hemodialysis patients. Kidney Int 45:1397-1400, 1994
33. TÖRNIG J, GROSS ML, SIMONAVICIENE A, et al: Hypertrophy of intramyocardial arteriolar smooth muscle cells in experimental renal failure. J Am Soc Nephrol 10:77-83, 1999
34. AMANN K, TÖRNIG J, FLECHTENMACHER C, et al: Blood-pressure- independent wall thickening of intramyocardial arterioles in experimental uremia: Evidence for a permissive action of PTH. Nephrol Dial Transplant 10:2043-2048, 1995
35. AMANN K, MILTENBERGER-MILTENYI G, SIMONAVICIENE A, et al: Remodeling of resistance arteries in renal failure - Effect of endothelin receptor blockade. J Am Soc Nephrol 12:2040-2050, 2001
36. AMANN K, WIEST G, ZIMMER G, et al: Reduced capillary density in the myocardium of uremic rats - A stereological study. Kidney Int 42:1079-1085, 1992
37. AMANN K, BREITBACH M, RITZ E, MALL G: Myocyte/capillary mismatch in the heart of uremic patients. J Am Soc Nephrol 9:1018-1022, 1998
38. NIELSEN AL, JENSEN HA, HEBGRANT J, et al: Oxygen status during haemodialysis. The Cord Group. Acta Anesthesiol Scand 107 (Suppl 1):195-200, 1995
39. KISHIMOTO T, TANAKA H, MACKAWA M, et al: Dialysis-induced hypoxaemia. Nephrol Dial Transplant 8(Suppl 2):25-29, 1993
40. CONVERSE RL, JR., JACOBSEN TN, JOST CMT, et al: Paradoxical withdrawal of reflex vasoconstriction as a cause of hemodialysis-induced hypotension. J Clin Invest 90:1657-1665, 1992
41. NISHIMURA M, TAKAHASHI H, MARUYAMA K, et al: Enhanced production of nitric oxide may be involved in acute hypotension during maintenance hemodialysis. Am J Kidney Dis 31:809-817, 1998
42. WANNER C, HOEL WH: Carnitine abnormalities in patients with renal insufficiency. Nephron 50:89-102, 1988
43. SAKURABAYASHI T, TAKAESU Y, HAGINOSHITA S, et al: Improvement of myocardial fatty acid metabolism through L-carnitine administration to chronic hemodialysis patients. Am J Nephrol 19:480-484, 1999
44. BARTEL LL, HUSSEY JL, SHRAGO E: Effect of dialysis on serum carnitine free fatty acids, and triglyceride levels in man and the rat. Metabolism 31:944-947, 1982
45. WESSEL-AAS T, BLOMHOFF JP, WIRUM E, NILSEN T: Hemodialysis and cell toxicity in vitro related to plasma triglycerides, post-heparin lipolytic activity and free fatty acids. Acta Med Scan 216:75-83, 1984
46. NOHARA R, HOSOKAWA R, HIRAI T, et al: Effect of metabolic substrate on BMIPP metabolism in canine myocardium. N Nucl Med 39:1132-1137, 1998
47. 123I-BMIPP for the diagnosis of coronary artery disease: Application of patients with diabetes and hyperlipidaemia. Nucl Med Commun 17:675-680, 1996
48. 201Tl uptake in chronically hypoperfused myocardium: Histologic correlation study. J Nucl Med 41:293-296, 2000